SIGN UP
LOG IN
News
KA
0.4861
+3.43%
0.0161
Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Shares of Wang & Lee Group, Inc. Rose sharply in today's pre-market trading after the company reported a year-over-year increase in FY23 financial results. Redwoods Acquisition Corp. Shares gained 141% to $17.83 in pre- market trading. Netflix Inc. Shares jumped around 32% on Thursday after reporting upbeat results for its first quarter.
Benzinga · 12h ago
Kineta Rolls Out New Stock and Cash Incentive Plans
TipRanks · 1d ago
Kineta Granted U.S. Patent Titled 'Proteasome activity enhancing compounds (including methods for treating cancer or tumors)'
Benzinga · 3d ago
Weekly Report: what happened at KA last week (0408-0412)?
Weekly Report · 4d ago
Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Medical Properties Trust, Inc. Shares jumped 13.1% in today's pre-market trading. The company announced it sold its majority interest in Utah Hospitals. LendingClub Corporation is expected to report earnings for the first quarter 2024 after the closing bell on Tuesday. Allarity Therapeutics shares rose 51% to $3.17 in pre- market trading.
Benzinga · 4d ago
Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Ascent Solar Technologies, Inc. (NASDAQ:ASTI) fell sharply during Wednesday's mid-day session. The company announced pricing of a $6 million public offering of shares at $0.14 per share. Marin Software Incorporated shares jumped 152% after the company announced upgrades to its integration with Microsoft Advertising.
Benzinga · 04/10 18:07
12 Health Care Stocks Moving In Wednesday's Intraday Session
Adial Pharmaceuticals (NASDAQ:ADIL) shares rose 61.6% to $1.83 during Wednesday's regular session. Orgenesis stock rose 27.83% and Jaguar Health shares rose 32.22% during the same period. Telomir Pharmaceuticals and Orgen Genesis were the biggest gainers in the company's stock.
Benzinga · 04/10 16:31
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
IN8bio stock increased by 47.7% to $1.61 during Wednesday's pre-market session. Jaguar Health (NASDAQ:JAGX) shares rose 25.0% during the session. China SXT Pharmaceuticals shares moved upwards by 24.85%. Losers in the market were BioSig Technologies and Kineta.
Benzinga · 04/10 12:09
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Tilray Brands, Inc. (NASDAQ:TLRY) fell sharply during Tuesday's session. The company missed third-quarter estimates and said it no longer expects to generate positive free cash flow for the full fiscal year 2024. Laser Photonics Corporation shares climbed 168% to $3.82.
Benzinga · 04/09 17:12
12 Health Care Stocks Moving In Tuesday's Intraday Session
Acrivon Therapeutics (NASDAQ:ACRV) stock moved upwards by 72.0% to $10.16 during Tuesday's regular session. BioSig Technologies stock increased by 27.41% and Tilray Brands stock decreased by 19.5%. The company's Q4 earnings report came out yesterday.
Benzinga · 04/09 16:31
BUZZ-Kineta jumps on positive early-stage tumor treatment trial
Kineta's KA.O shares rise 48.3% to 80 cents after market. Company says its therapy in combination with Merck's MRK.N Keytruda showed partial response in early-stage tumor treatment trial. KA says therapy showed favorable safety and tolerability.
Reuters · 04/08 20:54
KINETA INC: Current report
Press release · 04/08 20:20
Kineta Reports Progress in KVA12123 Cancer Trial
TipRanks · 04/08 20:12
Kineta Reports Initial Clinical Response Data At AACR 2024 Of Ongoing Phase 1/2 VISTA-101 Clinical Trial
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts. Favorable clinical safety and tolerability profile observed with no dose limiting toxicities. No evidence of CRS-associated cytokines observed at any dose level. Cleared fifth of six monotherapy and second of four combination cohorts.
Benzinga · 04/08 20:02
KINETA INC - NO EVIDENCE OF CRS-ASSOCIATED CYTOKINES OBSERVED AT ANY DOSE LEVEL
Reuters · 04/08 20:01
Weekly Report: what happened at KA last week (0401-0405)?
Weekly Report · 04/08 12:24
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Aesthetic Medical Intl (NASDAQ:AIH) shares rose 14.0% to $0.52 during Wednesday's after-market session. Kineta shares rose 8.46% and Simulations Plus shares increased by 6.74%. The company's market cap stands at $24.9 million.
Benzinga · 04/03 20:31
Weekly Report: what happened at KA last week (0325-0329)?
Weekly Report · 04/01 12:20
12 Health Care Stocks Moving In Monday's Intraday Session
Landos Biopharma (NASDAQ:LABP) shares rose 173.9% to $21.45 during Monday's regular session. The company's, Q4 earnings report came out 2 days ago. Sagimet Biosciences ( NASDAQ:SGMT) and XTL Biopharmaceuticals also moved upwards. Trxade Health stock decreased by 48.6% during the regular session to $12.38.
Benzinga · 03/25 17:30
Weekly Report: what happened at KA last week (0318-0322)?
Weekly Report · 03/25 12:23
More
Webull provides a variety of real-time KA stock news. You can receive the latest news about KINETA INC through multiple platforms. This information may help you make smarter investment decisions.
About KA
Kineta, Inc. is a clinical-stage biotechnology company. The Company has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a monoclonal antibody (mAb), immunotherapy targeting VISTA (V-domain Ig suppressor of T cell activation), and an anti-CD27 agonist mAb immunotherapy. KVA12123 may be an effective immunotherapy for many types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), ovarian cancer (OC), renal cell carcinoma (RCC) and head and neck squamous cell carcinoma. It is also developing an anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The nominated lead candidate is a fully human mAb that demonstrates nanomolar (nM) binding affinity to CD27 in humans.